Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01286987
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: Talazoparib

Indicates status has not been verified in more than two years